Press Releases – Page 2 – Sanaria

Sanaria’s Malaria Vaccine Yields Unprecedented Protection In Clinical Trial

May 6, 2016 By Matt Feldman In Press Releases No Comments

Results of a clinical trial of Sanaria® PfSPZ (Plasmodium falciparum sporozoite) Vaccine to prevent malaria infections, published today in the online issue of Nature Medicine magazine, show that the vaccine provided protection against infection with malaria parasites for at least 14 months in subjects who were exposed to Plasmodium falciparum parasites. The findings put the Sanaria vaccine on track to be the first malaria vaccine providing durable protection against infection with malaria parasites. Plasmodium falciparum is the malaria parasite that causes about 438,000 deaths and 214 million cases annually.

Government Of Equatorial Guinea And Oil Companies Agree To $48.5 Million Funding Of Malaria Vaccine Development Program With Sanaria Inc.

June 29, 2015 By Matt Feldman In Press Releases No Comments

The Government of the Republic of Equatorial Guinea announced an agreement with industry partners, Marathon Oil Corporation, Noble Energy Inc. and AMPCO, to sponsor the clinical development of Sanaria® PfSPZ Vaccine against malaria, including a series of clinical trials from 2015 until 2018.

Cryoport and Sanaria Expand Logistics Partnership Supporting Malaria Vaccines distributed in Liquid Nitrogen Vapor Phase;

February 23, 2015 By Matt Feldman In Press Releases No Comments

Cryoport, Inc., the leading provider of advanced cryogenic logistics solutions for the life sciences industry, serving markets including immunotherapies, stem cells, cell lines, clinical research organizations, vaccine manufacturers and reproductive medicine, today announced that the Company is enhancing its cryogenic logistics support of its Sanaria partnership, which includes Sanaria’s production of malaria vaccine as well as its research and development efforts.

Sanaria Inc. To Launch Crowdfunding Campaign For Sporobottm, A Mosquito-Dissecting Robot For Accelerating Manufacture Of Sanaria’s Malaria Vaccine

April 30, 2014 By Matt Feldman In Press Releases No Comments

Biotechnology company Sanaria Inc. aims to raise at least $250,000 in 30 days on Indiegogo.com, a crowdfunding website. The campaign launches on May 6, 2014. Funds will be dedicated to the development of SporoBotTM, a robot that will dissect mosquito salivary glands. By replacing manual microdissection of mosquito salivary glands, SporobotTM will automate a key step in the manufacturing process of Sanaria® PfSPZ Vaccine against malaria.

Sanaria® PfSPZ Malaria Vaccine Wins 2014 Vaccine Industry Excellence Award for “Best Prophylactic Vaccine”

March 1, 2014 By Matt Feldman In Press Releases No Comments

Sanaria received the 2014 Vaccine Industry Excellence Award for the “Best Prophylactic Vaccine” at a ceremony held March 25 in Washington DC during the 14th World Vaccine Congress. Vaccines from Sanofi Pasteur, GSK, and Novartis were among the 6 finalists competing with Sanaria.

Sanaria’s Malaria Vaccine Yields Unprecedented Protection In Phase 1 Clinical Trial

August 8, 2013 By Matt Feldman In Press Releases No Comments

Results of a phase I clinical trial of the Sanaria® PfSPZ Vaccine to combat malaria, published today in the online issue of Science magazine, show that the vaccine provided complete protection against malaria in subjects who were exposed to Plasmodium falciparum parasites.

NF135.C10: a new Plasmodium falciparum clone for controlled human malaria infections

December 27, 2012 By Matt Feldman In Press Releases No Comments

Read the new paper published in Journal of Infectious Diseases.

Abstract

We established a new field clone of Plasmodium falciparum for use in controlled human malaria infections and vaccine studies to complement the current small portfolio of P. falciparum strains, primarily based on NF54. The Cambodian clone NF135.C10 consistently produced gametocytes and generated substantial numbers of sporozoites in Anopheles mosquitoes and diverged from NF54 parasites by genetic markers. In a controlled human malaria infection trial, 3 of 5 volunteers challenged by mosquitoes infected with NF135.C10 and 4 of 5 challenged with NF54 developed parasitemia as detected with microscopy. The |

Malaria Vaccine Developer Sanaria Inc. and the Institute for Bioscience and Biotechnology Research of the University of Maryland College Park Awarded Collaborative, US $3M NIH Phase II Small Business Innovation Research Grant

June 13, 2012 By Matt Feldman In Press Releases No Comments

Sanaria Inc., a privately held company in Rockville, Maryland, and the Institute for Bioscience and Biotechnology Research (IBBR) of the University of Maryland College Park announce the receipt of a multi-year Phase II Small Business Innovation Research (SBIR) Grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). The grant, worth nearly $3 million over a 3 year period, will fund research and development to genetically engineer mosquitoes that produce large numbers of parasites for Sanaria’s malaria vaccine manufacturing process.

Quantitative assessment of Plasmodium falciparum sexual development reveals potent transmission- blocking activity by methylene blue

November 22, 2011 By Matt Feldman In Press Releases No Comments

Clinical studies and mathematical models predict that, to achieve malaria elimination, combination therapies will need to incorporate drugs that block the transmission of Plasmodium falciparum sexual stage parasites to mosquito vectors. Efforts to measure the activity of existing antimalarials on intraerythrocytic sexual stage gametocytes and identify transmission-blocking agents have, until now, been hindered by a lack of quantitative assays. Here, we report an experimental system using P. falciparum lines that stably express gametocyte-specific GFP-luciferase reporters, which enable the assessment of dose- and time-dependent drug action on gametocyte maturation and transmission.

Initial Trial Of Sanaria’s Malaria Vaccine Yields Positive Results

September 8, 2011 By Matt Feldman In Press Releases No Comments

Positive results from the initial Phase 1 clinical trial in 80 healthy volunteers and complementary pre-clinical studies of the Sanaria® PfSPZ Vaccine are published today in the online issue of Science (www.sciencexpress.org).

Medicine in Need (MEND) receives $3 million grant from the Bill and Melinda Gates Foundation to apply advanced formulation technologies to the stabilization of new malaria vaccine candidates, including Sanaria’s PfSPZ vaccine

June 3, 2010 By Matt Feldman In News, Press Releases No Comments

Medicine in Need (MEND) receives $3 million grant from the Bill and Melinda Gates Foundation to apply advanced formulation technologies to the stabilization of new malaria vaccine candidates, including Sanaria's PfSPZ vaccine.

Sanaria Inc. Receives Multi-Year U.S. NIH Phase II Small Business Innovation Research Grant to Develop a Genetically Attenuated Whole Parasite Malaria Vaccine

February 23, 2010 By Matt Feldman In Press Releases No Comments

Sanaria Inc. has received additional support from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health in the form of a Phase II Small Business Innovation Research (SBIR) Grant. The three-year award totaling approximately $3 million will support collaborative research by investigators at Sanaria and Columbia University.

Sanaria Inc. Receives Multi-Year U.S. NIH Phase II Small Business Innovation Research Grant to Enhance Efficiency and Scale-up of its Malaria Vaccine Manufacturing Process

September 16, 2009 By Matt Feldman In Press Releases No Comments

Sanaria Inc. has received additional support from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health in the form of a Phase II Small Business Innovation Research (SBIR) Grant. The award for two years is $1.99 million.

Malaria Vaccine Developer, Sanaria Inc., receives 2009 Vaccine Industry Excellence Award for Best Early-Stage Vaccine Biotech

June 2, 2009 By Matt Feldman In Press Releases No Comments

The award was announced on April 21, 2009 at the World Vaccine Congress Washington conference. The Vaccine Industry Excellence awards recognize the accomplishments and contributions of companies and individuals working in the vaccine industry. Sanaria was named Best Early-Stage Vaccine Biotech from a group of nine companies shortlisted for the award. Other awardees included GlaxoSmithKline Biologicals for Best Vaccine R&D Pipeline and Merck for Best Prophylactic Vaccine.

Phase 1 trial of whole-parasite malaria vaccine to begin

April 23, 2009 By Matt Feldman In Press Releases No Comments

FDA approval for testing in humans watershed moment for unique malaria vaccine approach

ROCKVILLE, Maryland – In a move that highlights the strength of public-private collaboration in tackling international health challenges, the Maryland- based company Sanaria Inc., with support from the PATH Malaria Vaccine Initiative (MVI), has initiated a Phase 1 clinical trial—the first tests in adult volunteers—of its unique malaria vaccine candidate. Unlike other malaria vaccine candidates, Sanaria’s approach deploys a weakened form of the whole malaria parasite harvested from irradiated mosquitoes instead of small portions of the parasite.

Having met the US Food and Drug Administration’s (FDA) |

Sanaria and TI Pharma collaborators at Radboud University Nijmegen Medical Centre and Leiden University Medical Centre publish the first report of genetically attenuated P. falciparum sporozoites

October 30, 2008 By Matt Feldman In Press Releases No Comments

Every day 2000 children die from malaria in Africa alone. The infec6on is transmi9ed from human to human by bi6ng mosquitoes and remains one of the world’s most devasta6ng diseases. Despite many years of effort a vaccine is s6ll not available but is urgently needed, if we are to make an impact on this enormous problem.

Sanaria and the University of Maryland Biotechnology Institute awarded collaborative, multi-year, US $600,000 NIH SBIR grant

July 29, 2008 By Matt Feldman In Press Releases No Comments

Sanaria Inc., a privately held company in Rockville, Maryland, and the University of Maryland Biotechnology Institute (UMBI) announced the receipt of a multi-year Small Business Innovation Research (SBIR) Grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health.

Malaria vaccine developer Sanaria Inc. receives the Technology Council of Maryland’s Emerging Company of the Year Award.

May 15, 2008 By Matt Feldman In Press Releases No Comments

Sanaria Inc. was named Emerging Company of the Year at the annual Technology Council of Maryland’s Tech Awards Celebration honoring the state’s technology leaders and organizations.

Sanaria, Top Institute Pharma, Radboud University Nijmegen Medical Centre and Leiden University Medical Center enter into $23.6 million research agreement

January 16, 2008 By Matt Feldman In Press Releases No Comments

Today Top Institute Pharma announces a highly promising research project that is aimed at the development of a malaria vaccine. This TI Pharma project will be an expansion of extremely promising findings from previous studies.

Sanaria, PATH Malaria Vaccine Initiative Open Manufacturing Facility For Producing World’s First “Whole-Parasite” Malaria Vaccine

October 26, 2007 By Matt Feldman In Press Releases No Comments

Sanaria Inc. and the PATH Malaria Vaccine Initiative today officially opened a one-of-a-kind clinical manufacturing facility to produce a vaccine that uses a weakened form of the malaria parasite to fight a disease that annually kills more than one million people, most of them African children.

Contact Us

We welcome your feedback and inquiries. Please be in touch.

Address:

Sanaria Inc.
9610 Medical Center Drive, Suite 200
Rockville, MD 20850

Phone:

+1.301.770.3222

Email:

sanaria@sanaria.com

Social: